Perspective Therapeutics presents interim Phase 1/2a monotherapy data for VMT01 in advanced melanoma at SITC 2026

Perspective Therapeutics announced updated interim monotherapy results from its ongoing Phase 1/2a trial of [212Pb]lapemelanotide zapixetar (VMT01), a targeted alpha therapy, presented as a poster at the SITC 41st Annual Meeting. The data covered 20 patients with heavily pretreated advanced melanoma.

Detected & updated continuously · Source: Nebula